Journal article icon

Journal article

Abiraterone acetate: a potential source of interference in testosterone assays.

Abstract:

Prostate cancer is the second most common cause of cancer in the UK with one in eight men diagnosed during their lifetime. Prostate cancer is typically dependent on androgens for growth, survival and metastasis. Androgen deprivation therapy targets this dependency through drugs such as luteinizing hormone-releasing hormone (LHRH) agonists, which result in inhibition of testicular testosterone. Castrate-resistant prostate cancer (CRPC) describes tumour growth occurring when serum testosterone ...

Expand abstract
Publication status:
Published
Peer review status:
Reviewed (other)

Actions


Access Document


Publisher copy:
10.1515/cclm-2017-0631

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
ORCID:
0000-0001-9413-0575
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
RDM; OCDEM
Role:
Author
Publisher:
De Gruyter
Journal:
Clinical Chemistry and Laboratory Medicine More from this journal
Publication date:
2018-01-01
Acceptance date:
2017-11-27
DOI:
EISSN:
1437-4331
ISSN:
1434-6621
Pmid:
29303767
Language:
English
Keywords:
Pubs id:
pubs:817748
UUID:
uuid:69901c4c-c2ab-4d9c-8645-13a81c51fa62
Local pid:
pubs:817748
Source identifiers:
817748
Deposit date:
2018-03-05

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP